Lindy Fishburne, managing partner of Breakout Ventures, sits down with Neil to discuss investing in seed- and early-stage bioscience companies, and what she learned working with entrepreneurial scientists at Breakout Labs.

Eric Topol, founder and director of the Scripps Research Translational Institute, sits down with Neil to discuss the COVID-19 delta variant, our failures to evolve with the virus, and what steps need to be taken to combat the ongoing pandemic.

Pete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.

James Valentine, an attorney with Hyman, Phelps & McNamara specializing in regulatory law, sits down with Neil to discuss the FDA’s accelerated approval of Biogen’s Aduhelm for Alzheimer’s disease and offers a contrarian take on the controversy.

Juan Scarlett, managing director of OneValley Ventures, sits down with Neil to discusses OneValley's efforts to democratize entrepreneurship and his approach investing in pre-seed and seed funding rounds.

Amy DuRoss, co-founder and CEO of Vineti, sits down with Neil to discuss how the company’s platform technology addresses the unique supply chain management challenges of cell and gene therapy companies.

Brian Culley, CEO of Lineage Cell Therapeutics, sits down with Neil to discuss his company’s efforts to develop off-the-shelf cell therapies to treat degenerative retinal disease, spinal cord injury, and cancer.

Craig Laferrière head of vaccine development for Novateur Ventures, joins Neil to discuss the relative strengths and weaknesses of the different COVID-19 vaccines in use and in development.

Rachel Kuperman, CEO of Eysz, sits down with Neil to discuss her company’s efforts to develop a digital health platform using passive eye-movements as input to measure, diagnose, and predict neurological disease starting with epilepsy.

Anthony DePasqua, CEO of EnClear Therapies, sits down with Neil to discuss the company’s technology in development to remove toxic proteins from cerebrospinal spinal fluid to treat patients with ALS and other neurodegenerative conditions.